Maxim Group initiated coverage on RenovoRx with a new price target
$RNXT
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group initiated coverage of RenovoRx with a rating of Buy and set a new price target of $15.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2021 | $16.00 | Buy | Roth Capital |
| 10/6/2021 | $15.00 | Buy | Maxim Group |
RenovoCath is proudly made in America at a facility in North Barrington, IL RenovoRx management and board members purchased over 140,000 shares of RenovoRx stock during recent open trading window, signaling their confidence in RenovoRx's future RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced that it is increasing production of its FDA-cleared RenovoCath catheter-based device in order to meet increased demand for the targeted delivery of diagnostic and/or therapeutic agents from oncologists and interventional radiol
CEO Shaun Bagai to discuss the momentum of RenovoRx's commercialization efforts for its RenovoCath® device, including an update on initial revenues generated, and continued progress on the ongoing Phase III TIGeR-PaC clinical trial RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will present at the LD Micro Invitational XV: New York 2025 conference taking place at the Westin Grand Central Hotel, New York, NY on April 10, 2025. Mr. Bagai will discuss recent corporate mileston
Revenues from RenovoCath Expected to Grow Sequentially During 2025 with Expansion of New Customer Purchase Orders and Customer Reorders Completion of TIGeR-PaC Clinical Trial Enrollment and Review of Second Interim Analysis by Data Monitoring Committee on Target for 2025 Reports 2024 Financial Results Including $7.2 Million Cash Position as of December 31, 2024, with Additional $12.1 Million in Gross Proceeds Raised in February 2025 Company to Host Fireside Chat on Thursday, April 3rd at 12 p.m. ET RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared dru
Roth Capital initiated coverage of RenovoRx with a rating of Buy and set a new price target of $16.00
Maxim Group initiated coverage of RenovoRx with a rating of Buy and set a new price target of $15.00
4 - RenovoRx, Inc. (0001574094) (Issuer)
4 - RenovoRx, Inc. (0001574094) (Issuer)
4 - RenovoRx, Inc. (0001574094) (Issuer)
8-K - RenovoRx, Inc. (0001574094) (Filer)
10-K - RenovoRx, Inc. (0001574094) (Filer)
NT 10-K - RenovoRx, Inc. (0001574094) (Filer)
SC 13G/A - RenovoRx, Inc. (0001574094) (Subject)
SC 13G - RenovoRx, Inc. (0001574094) (Subject)
SC 13G - RenovoRx, Inc. (0001574094) (Subject)
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA
With Material Participation From Insiders, Offering Proceeds to Help Drive Company Towards Second Interim Analysis of the Pivotal TIGeR-PaC Phase III Clinical Trial by Late 2024 RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the "private placement" or the "financing") resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses. The closing of this private placement extends RenovoRx's cash runway as RenovoRx continues its ongoing pivotal TIGeR-PaC Phase III c
RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company's Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ESMO GI. Dr. Ducreux was trained in medicine, gastroenterology, and gastrointestinal tract oncology at the University of Paris Sud. Dr. Ducreux earned his master's degree in biological sciences and PhD in health sciences. He has held pre
4 - RenovoRx, Inc. (0001574094) (Issuer)
4 - RenovoRx, Inc. (0001574094) (Issuer)
4 - RenovoRx, Inc. (0001574094) (Issuer)